.png){kind=icon}
返回
CAR-T cell potency: from structural elements to vector backbone components
.png){kind=icon}
OA
AI
DOI：10.1186/s40364-022-00417-w.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Chimeric antigen receptor (CAR) T cell therapy, in which a patient's own T lymphocytes are engineered to recognize and kill cancer cells, has achieved remarkable success in some hematological malignancies in preclinical and clinical trials, resulting in six FDA-approved CAR-T products currently available in the market. Once equipped with a CAR construct, T cells act as living drugs and recognize and eliminate the target tumor cells in an MHC-independent manner. In this review, we first described all structural modular of CAR in detail, focusing on more recent findings. We then pointed out behind-the-scene elements contributing to CAR expression and reviewed how CAR expression can be drastically affected by the elements embedded in the viral vector backbone.
Keyword:
Chimeric antigen receptor
Cancer immunotherapy
Single-chain variable fragment
Nanobody
Lentiviral vectors
Signal peptide
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
B
IF:
11.5
论文数:
925
被引数:
5.0K
机构
引用论文
.png){kind=icon}
Percutaneous ethanol treatment of hepatocellular carcinoma (HCC): large volumes for large tumors
PREAI
分享收藏
查看更多内容